SORAFENIB TOSYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Sorafenib Tosylate patents expire, and what generic alternatives are available?
Sorafenib Tosylate is a drug marketed by Dr Reddys, Mylan, Teva Pharms Usa Inc, Torrent, and Yabao Pharm. and is included in five NDAs.
The generic ingredient in SORAFENIB TOSYLATE is sorafenib tosylate. There are thirteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the sorafenib tosylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sorafenib Tosylate
A generic version of SORAFENIB TOSYLATE was approved as sorafenib tosylate by MYLAN on September 10th, 2020.
Summary for SORAFENIB TOSYLATE
Recent Clinical Trials for SORAFENIB TOSYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The First Affiliated Hospital of Nanchang University | Phase 2/Phase 3 |
Guangzhou First People's Hospital | Phase 2/Phase 3 |
Second Xiangya Hospital of Central South University | Phase 2/Phase 3 |
Pharmacology for SORAFENIB TOSYLATE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for SORAFENIB TOSYLATE
Paragraph IV (Patent) Challenges for SORAFENIB TOSYLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NEXAVAR | Tablets | sorafenib tosylate | 200 mg | 021923 | 1 | 2014-02-28 |